Nelson Advisors: Specialists in European HealthTech, MedTech, Healthcare AI and Digital Health. Partnerships, Investments, Mergers & Acquisitions from $25M to $250M Enterprise Value
A market in structural realignment
The European healthcare technology M&A landscape is undergoing a structural realignment, and it is happening quietly. There is no single headline moment to point to, no dramatic collapse or blockbuster deal that marks the shift. Instead, the change has been cumulative: a gradual hollowing out of specialist advisory capacity in precisely the part of the market where most European HealthTech and MedTech companies actually live.
At the top of the market, bulge bracket institutions have concentrated their healthcare franchises on billion-euro mega deals. The economics of a global bank make this inevitable. When a deal team's cost base is calibrated to transactions with fees measured in tens of millions, a €60M sale of a digital therapeutics business or a €120M carve-out of a connected device platform does not clear the internal hurdle, however interesting the asset may be. These businesses receive polite interest, perhaps an introductory call, and then a gentle redirection elsewhere.
In the middle of the market, generalist mid-market banks face a different problem. They have the appetite for transactions of this size, but healthcare technology is a difficult sector to advise on without deep domain fluency. A clinical-grade software product is not a SaaS business with a medical label attached. A medical device with an embedded AI algorithm is not simply hardware with software features.
Regulatory pathways, reimbursement dynamics, evidence generation, data governance, clinical validation and the peculiar buying behaviour of health systems all shape valuation in ways that a generalist technology framework cannot capture. Buyers know this. Boards know this. Founders learn it, sometimes painfully, when a process stalls because the adviser could not articulate why an asset was worth what its owners believed it to be worth.
Between these two forces, a distinct gap has opened in the lower to mid market, the $25M to $250M Enterprise Value band that represents the vast majority of European healthcare technology companies by number. This is where founder-led businesses reach the point of a strategic decision. This is where venture-backed companies seek their next stage of growth capital or a strategic home. This is where corporate development teams at global MedTech and pharma groups look for the acquisitions that will renew their portfolios. And this is where the demand for specialist advice has consistently outstripped the supply.
Nelson Advisors was built for exactly this segment. Not adapted to it, not stretched to cover it as an afterthought, but purpose built from the outset to serve European HealthTech, MedTech, Healthcare AI and Digital Health companies in the lower to middle market with the depth of sector expertise that these transactions demand.
Sector exclusivity as a strategic choice
The decision to be sector exclusive is the single most important choice Nelson Advisors has made, and it deserves some explanation because it runs against the instincts of most advisory businesses.
The conventional logic of a boutique investment bank is to diversify. A firm that advises across technology, business services, consumer and industrials can weather a downturn in any one sector and can draw on a wider pool of potential mandates. Sector exclusivity, by contrast, concentrates risk. When healthcare technology valuations compress, as they did through parts of the post-pandemic reset, an exclusive healthcare technology adviser feels it directly.
Nelson Advisors accepted that trade-off deliberately, because the alternative would have compromised the one thing that matters most to the founders, investors and boards it serves: the ability to price, position and sell a clinical asset with complete credibility.
Sector exclusivity means that every conversation the firm has, every buyer relationship it maintains, every piece of market intelligence it gathers and every transaction it executes compounds within the same domain. When a Nelson Advisors team member speaks with the corporate development function of a global medical device group, they are continuing a relationship rather than starting one.
When they build a valuation framework for a remote patient monitoring business, they are drawing on comparable transactions they have seen first-hand, not on a database extract. When they advise a board on the likely regulatory posture of a strategic acquirer toward a Software as a Medical Device product, they are speaking from direct experience of how those acquirers actually behave in diligence.
This depth is difficult to replicate. A generalist firm can hire a healthcare specialist, but that individual sits within an organisation whose systems, relationships and instincts are calibrated to other sectors. An exclusive firm is calibrated to healthcare technology from the ground up. Over time, that calibration becomes a form of institutional knowledge that clients can feel in the quality of advice they receive.
Founding Partners who have lived the founder's journey
Reputation in advisory work is earned through outcomes, but it begins with credibility, and the credibility of Nelson Advisors rests first on the experience of its Founding Partners, Lloyd Price and Paul Hemings.
Since 2012, Lloyd and Paul have built, scaled and sold four HealthTech businesses. These were not passive investments or board seats held at a distance. They were operating ventures in which the Founding Partners were directly responsible for product strategy, commercial execution, fundraising, team building and ultimately the exit process itself. The four exits span four distinct corners of the healthcare technology landscape: Patient Engagement, Medical Device Cybersecurity, Metabolic Health and Consumer Healthcare.
Each of these markets taught something different. Patient Engagement exposed the realities of selling into health systems, where procurement cycles are long, clinical champions are essential and the gap between a pilot and an enterprise contract can swallow a company's runway. Medical Device Cybersecurity revealed how regulatory pressure creates markets almost overnight, and how strategic acquirers value capabilities that close compliance gaps in their own portfolios.
Metabolic Health demonstrated the power of outcomes data in a market crowded with wellness claims, and the premium that acquirers place on evidence over marketing. Consumer Healthcare showed how direct-to-consumer economics interact with clinical credibility, and how brands that manage to hold both can command valuations that pure consumer or pure clinical businesses cannot.
The cumulative effect of these experiences is an advisory perspective that is unusual in investment banking. Most bankers have never sat on the founder's side of a term sheet negotiation. Most have never had to decide whether to accept a lower headline price with cleaner terms or hold out for a higher number with more earn-out risk. Most have never felt the particular pressure of a process that is running while the business still has to hit its quarterly numbers, retain its key engineers and keep its clinical partners engaged.
Lloyd and Paul have done all of this, four times over. When they advise a founder on how to structure a sale, they are drawing on decisions they made themselves, with their own equity at stake. When they tell a board that a particular buyer is likely to retrade on price after diligence, they are recognising a pattern they have encountered directly. When they counsel patience in a process, or urgency, the advice carries the weight of lived experience rather than theoretical models.
This is the foundation of the firm's reputation amongst founders. Founders talk to one another, and the consistent message that emerges from those conversations is that Nelson Advisors understands the founder's position from the inside. That understanding is not a marketing claim. It is a matter of record.
A team built from the best of banking, science and operating experience
The Founding Partners set the tone, but the Nelson Advisors team as a whole is what delivers transactions. The firm has assembled a group of Directors and Analysts whose backgrounds combine the rigour of top-tier investment banking with scientific depth and hands-on operating experience in healthcare.
On the banking side, the team includes professionals whose careers were shaped at Rothschild, Citi and Morgan Stanley. These institutions instil a particular discipline in transaction execution: the construction of an information memorandum that anticipates every buyer question, the management of a competitive process that maintains tension without alienating serious bidders, the negotiation of a share purchase agreement in which the warranties, indemnities and earn-out mechanics are understood as deeply as the headline price. This discipline is what distinguishes a well-run process from a merely adequate one, and it is what allows Nelson Advisors to bring bulge bracket execution standards to transactions that bulge bracket banks will not touch.
On the scientific and investment side, the team draws on experience from ETH Zurich, one of Europe's leading technical universities, and from Kieger and redalpine, investors with deep roots in Swiss and European healthcare and technology venture capital. This experience matters because so many of the assets Nelson Advisors advises on are, at their core, scientific propositions.
An adviser who can read a clinical study, understand the statistical power of a trial, evaluate the defensibility of an algorithm or assess the regulatory strategy of a device company is an adviser who can engage with buyers on their own terms. The venture perspective adds a further dimension: an understanding of how investors think about stage, risk and return, which is invaluable when a transaction involves growth capital or a partial exit alongside a strategic partnership.
On the operating side, the team includes professionals who have worked within Ethicon, Johnson & Johnson and Bristol Myers Squibb. This corporate experience is perhaps the least visible but most consequential element of the firm's capability. Global MedTech and pharma organisations have their own logic: their own strategic planning cycles, their own criteria for business development, their own internal politics around acquisitions and their own way of conducting diligence.
Team members who have sat inside these organisations understand how a proposed acquisition moves through a corporate development committee, what a business unit leader needs to see to sponsor a deal and where the friction points lie. That understanding shapes how Nelson Advisors positions assets to strategic buyers and how it anticipates the questions that will arise long before they are asked.
Across the team, academic achievement is consistently high. The firm's professionals hold MBAs, MScs and PhDs, and the combination of these qualifications with decades of aggregate experience in investment banking, financial analysis, investor relations and entrepreneurial ventures produces a rare blend. It is a team that can build a discounted cash flow model, interpret a regulatory submission, brief a board on investor sentiment and negotiate a deal, all within the same engagement and often within the same meeting.
Reputation amongst investors
Founders are one constituency. Investors are another, and their assessment of an adviser is shaped by different priorities.
Venture capital and growth equity investors in European healthcare technology have, over the past several years, become increasingly discerning about the advisers they work with. The reason is simple: an exit process is the moment at which years of capital and effort are converted into returns, and the quality of that process has a direct effect on fund performance. An adviser who runs a poorly targeted process, mis-prices the asset or fails to maintain competitive tension can cost an investor a meaningful portion of their return on a position.
Nelson Advisors has earned the confidence of investors by treating every process as an exercise in precision. Buyer identification is the first test. In healthcare technology, the universe of credible acquirers for any given asset is narrower than in generalist technology, and it is also more heterogeneous. A digital health platform might attract interest from a global MedTech group seeking a software layer, a pharmaceutical company building a patient services capability, a health insurer looking to reduce claims cost, a private equity firm consolidating a category, or a larger digital health company pursuing a roll-up strategy.
Each of these buyer types values the asset differently, conducts diligence differently and structures deals differently. An adviser who understands these differences can construct a process that surfaces the best possible outcome. An adviser who does not will default to a generic approach that leaves value on the table.
Investors also value candour. One of the recurring themes in the firm's investor relationships is that Nelson Advisors will tell a board what it needs to hear rather than what it wants to hear. If an asset is not ready for a sale process, the firm will say so and explain what needs to change. If a valuation expectation is unrealistic given current market conditions, the firm will present the evidence rather than simply accept the mandate and hope for the best. This can occasionally cost the firm an engagement in the short term. Over the long term, it is precisely what builds the trust that leads investors to return with their next portfolio company.
The firm's activity in growth investments and partnerships, alongside pure M&A, adds a further dimension to its investor relationships. Not every transaction in the lower to mid market is an outright sale. Many companies at the $25M to $250M scale are seeking a strategic partner, a minority investment from a corporate, or a structured growth round that positions them for a larger exit in several years' time.
Nelson Advisors advises across this full spectrum, which means that investors can engage the firm at multiple points in a portfolio company's lifecycle rather than only at the end.
Reputation amongst boards
The third constituency is the board, and here the firm's reputation rests on governance and judgement.
Boards of healthcare technology companies carry a particular burden. They are often composed of a mix of founders, investor representatives, independent directors with clinical or commercial backgrounds and, in some cases, representatives of strategic shareholders. Their interests are aligned in principle but frequently diverge in practice, especially when a strategic decision is on the table. The founder may want to continue building. An early investor may want liquidity. A later investor may want to hold for a larger exit. An independent director may be concerned about execution risk in either direction.
An adviser to a board in this situation must be able to do several things at once: present a clear and objective analysis of the strategic options, help the board understand the likely outcomes of each, facilitate a decision that all stakeholders can support and then execute that decision with discipline. This requires a combination of analytical rigour, interpersonal judgement and an understanding of governance that goes beyond transaction mechanics.
Nelson Advisors has cultivated this capability deliberately. The firm's approach to board advisory begins with a strategic review rather than a pitch. Before recommending a course of action, the firm works with the board to understand the company's position, the market context, the shareholder dynamics and the realistic range of outcomes. This work is often the most valuable part of an engagement, because it gives the board a shared factual foundation on which to make a decision. Once that decision is made, the firm's execution discipline takes over, but the foundation of trust has already been established.
Boards also value the firm's independence. Because Nelson Advisors is not part of a larger financial institution, it has no competing interests in lending, trading or asset management that might colour its advice. Its only interest is in delivering the best outcome for its client. This is a simple proposition, but it carries considerable weight with directors who have experienced the conflicts that can arise within larger institutions.
Contributing to the next generation
One element of the firm's identity that sits outside its transaction work, but is inseparable from its reputation, is the commitment of the Founding Partners to education.
Lloyd and Paul regularly mentor MBA students and guest lecture at leading business schools across the UK and Europe, including University College London's Global Business School for Health, the University of Oxford, the University of Cambridge, London Business School and IESE Business School in Barcelona. These engagements cover the practical realities of building, funding and selling healthcare technology companies: how to think about market entry in a regulated sector, how to structure a cap table that survives multiple funding rounds, how to prepare a business for an exit and how the M&A process actually unfolds from the inside.
This work is not incidental to the firm's business. It reflects a belief that the European healthcare technology ecosystem benefits when its future founders, investors and executives understand the full arc of a company's life, including the strategic transaction that so often marks its transition to a larger platform. It also keeps the Founding Partners in close contact with the emerging generation of talent in the sector, many of whom go on to found or join the companies that will become the firm's clients and counterparties in years to come.
The relationships that emerge from mentoring and lecturing are long-term by nature. A student who attends a guest lecture at UCL's Global Business School for Health or a workshop at IESE may not need an adviser for a decade. When they do, they will remember who took the time to explain how the market works when there was no transaction to be had. This is reputation built patiently, in the way that reputation in advisory work must be built.
What the lower to mid market actually needs
It is worth returning to the structural gap described at the outset, because the firm's positioning within it is what makes the rest of its capabilities relevant.
The lower to mid market in European healthcare technology is not a scaled-down version of the large-cap market. It has its own characteristics. Companies at this scale are often still founder-led, with founders who hold significant equity and strong views about the future of the business. They are frequently venture-backed, with investor syndicates that span multiple funds and multiple geographies. They operate in a regulatory environment that differs across the UK, the EU and the various national health systems within it.
They sell into buyers, whether health systems, payers, pharma companies or consumers, whose purchasing behaviour is idiosyncratic and slow. And they are valued by acquirers who are themselves diverse: global strategics, mid-cap consolidators, private equity sponsors and, increasingly, larger digital health companies with their own acquisition strategies.
Serving this market well requires an adviser who can engage with all of these dimensions. It requires a firm small enough to give senior attention to every mandate, but capable enough to run a competitive international process against well-resourced buyers. It requires sector knowledge deep enough to price clinical and regulatory risk accurately, and commercial judgement sharp enough to recognise when a buyer's interest is real.
It requires the ability to advise on partnerships and investments as well as outright sales, because the optimal path for a company at this scale is not always a sale. And it requires a reputation that gives founders, investors and boards the confidence to entrust the firm with the most important transaction in a company's history.
Nelson Advisors has built its practice around these requirements. The firm's sector exclusivity ensures depth. The Founding Partners' four exits ensure empathy with the founder's position. The team's blend of banking, scientific and operating backgrounds ensures execution quality and buyer fluency. The firm's independence ensures objectivity. And its commitment to the wider ecosystem, through mentoring and teaching, ensures that its relationships extend well beyond the transactions it advises on today.
Looking ahead
The realignment of the European healthcare technology M&A market is unlikely to reverse. The forces that created the gap in the lower to mid market are structural: the cost base of large institutions, the difficulty of generalist banks in mastering clinical assets, and the sheer number of European HealthTech and MedTech companies that will reach a strategic inflection point over the coming years.
If anything, these forces are intensifying as Healthcare AI matures from experimental pilots into commercially deployed products with real revenue and real regulatory scrutiny, as Digital Health consolidates after a period of fragmentation, and as global MedTech groups renew their portfolios through acquisition rather than internal development alone.
For founders considering their options, for investors planning exits, and for boards weighing strategic alternatives, the choice of adviser will increasingly determine the outcome. The difference between a process run by a firm that understands healthcare technology from the inside and one run by a firm that is learning the sector on the client's time is not marginal. It is measured in valuation, in deal certainty, in the quality of the strategic partner secured and in the time and energy that management is able to devote to running the business while the process unfolds.
Nelson Advisors exists to close that gap. Sector exclusive, founder-informed, institutionally rigorous and independent, the firm is emerging as the specialist investment banking partner for European healthcare technology in the $25M to $250M Enterprise Value range, where the majority of the sector's companies live and where the need for genuine expertise has never been greater.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments